OTCPK:ABMT

Stock Analysis Report

Advanced Biomedical Technologies

Executive Summary

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Advanced Biomedical Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-69.5%

ABMT

1.9%

US Medical Equipment

0.4%

US Market


1 Year Return

-71.1%

ABMT

15.6%

US Medical Equipment

6.9%

US Market

Return vs Industry: ABMT underperformed the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: ABMT underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

ABMTIndustryMarket
7 Day-69.5%1.9%0.4%
30 Day22.0%-1.7%-1.1%
90 Day-50.0%-0.03%-0.5%
1 Year-71.1%-71.1%16.5%15.6%9.3%6.9%
3 Year-69.5%-69.5%72.1%66.9%45.8%36.4%
5 Year-85.8%-85.8%125.8%100.8%62.9%45.1%

Price Volatility Vs. Market

How volatile is Advanced Biomedical Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Advanced Biomedical Technologies undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Advanced Biomedical Technologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Advanced Biomedical Technologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ABMT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Advanced Biomedical Technologies regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Advanced Biomedical Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Advanced Biomedical Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of ABMT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Advanced Biomedical Technologies's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Advanced Biomedical Technologies performed over the past 5 years?

-0.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ABMT is unprofitable, and losses have increased over the past 5 years at a rate of -0.8% per year.

Accelerating Growth: Unable to compare ABMT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ABMT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: ABMT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: ABMT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ABMT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Advanced Biomedical Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: ABMT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ABMT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ABMT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ABMT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: ABMT has a high level of physical assets or inventory.

Debt Coverage by Assets: ABMT has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABMT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ABMT has less than a year of cash runway if free cash flow continues to reduce at historical rates of -32.4% each year


Next Steps

Dividend

What is Advanced Biomedical Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ABMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ABMT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ABMT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABMT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ABMT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Advanced Biomedical Technologies's salary, the management and board of directors tenure and is there insider trading?

8.4yrs

Average board tenure


CEO

Hui Wang (49yo)

0yrs

Tenure

US$36,770

Compensation

Ms. Hui Wang serves as the Chief Executive Officer and Controller of Advanced BioMedical Technologies, Inc. Ms. Wang serves as General Manager of Shenzhen Changhua. She started her career at Hainan Xinte P ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Hui's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Hui's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

8.4yrs

Average Tenure

49yo

Average Age

Experienced Board: ABMT's board of directors are considered experienced (8.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Chi Yu (45yo)

    President

    • Tenure: 0yrs
    • Compensation: US$21.10k
  • Kai Gui (49yo)

    Secretary

    • Tenure: 0yrs
    • Compensation: US$31.65k
  • Hui Wang (49yo)

    CEO, Controller & Director

    • Tenure: 0yrs
    • Compensation: US$36.77k
  • Shangli Liu

    Chairman of Scientific Board and Chief Medical Advisor of Greater China

    • Tenure: 0yrs
  • John Lynch

    Chief Officer of Dental Technologies

    • Tenure: 0yrs

Board Members

  • Chi Yu (45yo)

    President

    • Tenure: 0yrs
    • Compensation: US$21.10k
  • John Harrington (77yo)

    Chairman of Advisory Board

    • Tenure: 8.4yrs
  • Donald Varshine

    Member of Adviosry Board

    • Tenure: 8.4yrs
  • Kai Gui (49yo)

    Secretary

    • Tenure: 0yrs
    • Compensation: US$31.65k
  • Hui Wang (49yo)

    CEO, Controller & Director

    • Tenure: 0yrs
    • Compensation: US$36.77k
  • Shangli Liu

    Chairman of Scientific Board and Chief Medical Advisor of Greater China

    • Tenure: 0yrs
  • Lamont Woody

    Member of Adviosry Board

    • Tenure: 8.4yrs
  • Frank Pelaia

    Member of Adviosry Board

    • Tenure: 8.4yrs
  • Thomas Deberardino

    Member of Scientific Board

    • Tenure: 7.9yrs
  • Hani Awad

    Member of Scientific Board

    • Tenure: 7.9yrs

Company Information

Advanced Biomedical Technologies, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Advanced Biomedical Technologies, Inc.
  • Ticker: ABMT
  • Exchange: OTCPK
  • Founded: 2002
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$4.247m
  • Shares outstanding: 69.62m
  • Website: https://abtlafleur.com

Number of Employees


Location

  • Advanced Biomedical Technologies, Inc.
  • Empire State Building
  • 59th Floor
  • New York
  • New York
  • 10118
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ABMTOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 2009

Biography

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, which incl ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 00:15
End of Day Share Price2019/10/16 00:00
Earnings2019/07/31
Annual Earnings2018/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.